Day One.

 

THURSDAY, MARCH 17th, 2022

 

Tsar Dusan Ballroom

 

07:30-08:30

Registration

 

 

 

Session 1

 

SERBIS IN COVID ERA

 

Chairs:  Vesna BJEGOVIC-MIKANOVIC, Nebojsa LADJEVIC

 

08:30-08:50

Vaccination: prevention is better than cure

Emina MILOSEVIC, Serbia

 

08:50-09:10

Time to transform-perspectives of health policy

Vesna BJEGOVIC-MIKANOVIC, Serbia

 

09:10-09:35

COVID-19: What we’ve done well and what we could or should have done better-the 4 Ps

Jean-Louis VINCENT, Belgium

 

 

 

Session 2

 

Chairs: Petar SEFEROVIC, Nebojsa Lalic

 

09:35-10:00

Cardiovascular disease: shifting from treatment to prevention

Petar SEFEROVIC, Serbia

 

10:00-10:20

Cardiovascular disease prevention in clinical practice: up-to-date recommendations

Arsen RISTIC, Serbia

 

10:40-11:00

Quantifying atherogenic lipoproteins for lipid-lowering strategies

Sanja STANKOVIC, Serbia

 

11:00-11:20

Treatment of lipid disorders in prevention of atherosclerosis

Katarina LALIC, Serbia

 

11:20-11:40

Risk assessment of children and adolescents with heterozygous familial hypercholesterolaemia

Claudia STEFANUTTI, Italy

 

11:40-12:00

Exercise in prevention of cardiovascular diseases: from basic science

to applied investigation

Vladimir JAKOVLJEVIC, Serbia

 

12:00-12:45

Workshop ONE ROCHE

Rising to the global challenge of Alzheimer's disease-the power of biomarkers

 

Importance of early diagnosis in AD:The role of biomarkers

Prof. Elka STEFANOVA, MD, Neurology Clinic,

University Clinical Center of Serbia, Belgrade, Serbia

 

The power of biomarkers in AD-biochemical perspective

Prof. Sergio BERNARDINI, MD, University of Tor Vergata Hospital, Rome, Italy

 

 

 

 

12:45-13:15

OPENING CEREMONY

Welcome addresses

 

 

 

 

PLENARY LECTURE

 

13:15-13:45

Value of laboratory medicine in public health and patient care

Prof. Khosrow ADELI, Canada

 

 

 

13:45-14:30

Lunch break

 

 

 

 

Session 3

 

Chairs: Arsen RISTIC, Sanja STANKOVIC

 

14:30-14:50

Biomarkers for the prevention of heart failure

Damien GRUSON, Belgium

 

14:50-15:10

The emerging role of cardiac biomarkers in cardiovascular risk stratification

Christos VAROUNIS, Greece

 

15:10-15:30

Cost-effectiveness of screening a general population for cardiovascular risk with high-sensitivity troponin I

Paul JULICHER, Germany

 

 

 

Session 4

 

Chairs: Dragan DJURIC, Vladimir JAKOVLJEVIC

 

15:30-15:50

Deep learning evaluation of cardiac biomarkers- preventive digital health

Pradeep DABLA, India

 

15:50-16:10

Digital biomarkers in cardiology; basic principles and current application

Dejan MILASINOVIC, Serbia

 

16:10-16:30

Homocysteine, B group vitamins, and cardiovascular disease prevention

Dragan DJURIC, Serbia

 

16:30-16:50

Cardiovascular diseases: the genetic risk score and screening programs

Nevena VELJKOVIC, Serbia

 

 

 

Session 5

 

Chairs: Goran STEVANOVIC, Bojan JOVANOVIC

 

16:50-17:10

How to prevent antibiotic resistance?

Goran STEVANOVIC, Serbia

 

17:10-17:30

Infection prevention in the intensive care unit

Bojan JOVANOVIC, Serbia

 

17:30-17:50

Prevention of ventilation induced lung injury

Giacomo BELLANI, Italy

 

 

Session 6

 

Chairs: Ron VAN SCHAIK, Vangelis MANOLOUPULOS

 

17:50-19:50

Pharmacogenetic testing in preventing drug adverse events

Ron VAN SCHAIK, The Netherlands

 

Pharmacogenomics and personalized medicine of oral anticoagulant drugs

Vangelis MANOLOUPULOS, Greece

 

Pharmacogenetics and digital health strategy for the quaternary prevention of ADRs: Preliminary results on "MedeA" Spanish cohort

Adrian LLERENA, Spain

 

Pharmacogenetics and phenotyping of OATP1B1

Mikko NIEMI, Finland

 

Using HLA typing to prevent adverse drug reactions

Ann DALY, UK

 

 

 

Next day >